Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 1:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pharmacogenomic Clear all
Recruiting Not applicable Interventional

The Geriatric Emergency Department Pharmacologic Harm Prevention Project

NCT07216846
View directory record Official record
Conditions
Fall, Fall Accident, Poly Pharmacy, Adverse Drug Events, Pharmacogenomic Drug Interaction, Pharmacogenomic Testing
Interventions
DNA care pathway
Other
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years to 110 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 26, 2026, 1:06 PM EDT
Completed No phase listed Observational

Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy

NCT00442520
View directory record Official record
Conditions
Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT

NCT01006733
View directory record Official record
Conditions
Thromboembolism
Interventions
Pharmacogenetic, Target INR 1.8
Genetic · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,598 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
6
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 1 Interventional

A Study of Enzastaurin in Patients With Leukemia

NCT00452257
View directory record Official record
Conditions
Leukemia, Lymphocytic
Interventions
enzastaurin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Duarte, California • Chicago, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors

NCT02717507
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Carvedilol, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Not listed
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
86
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 26, 2026, 1:06 PM EDT
Terminated Phase 2 Interventional

Pharmacogenomic Study of Docetaxel and Cisplatin, Followed by Docetaxel, Cisplatin and Irradiation.

NCT00216008
View directory record Official record
Conditions
Esophageal Adenocarcinomas, Adenocarcinomas of the Gastroesophageal Junction
Interventions
docetaxel, cisplatin, radiation, surgery
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 26, 2026, 1:06 PM EDT
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomic Evaluation of Antihypertensive Responses

NCT00246519
View directory record Official record
Conditions
Hypertension
Interventions
Hydrochlorothiazide, Atenolol
Drug
Lead sponsor
University of Florida
Other
Eligibility
17 Years to 65 Years
Enrollment
1,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
3
States / cities
Gainesville, Florida • Atlanta, Georgia • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 26, 2026, 1:06 PM EDT
Active, not recruiting Phase 1 Interventional

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT02453620
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Preemptive Pharmacogenomics Testing Among Geriatric Patients

NCT05091879
View directory record Official record
Conditions
Polypharmacy, Pharmacogenomic Testing
Interventions
Multigene pharmacogenomics test
Genetic
Lead sponsor
Geisinger Clinic
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 26, 2026, 1:06 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

NCT01280825
View directory record Official record
Conditions
Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 26, 2026, 1:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pharmacogenetic Testing in Primary Care

NCT01600846
View directory record Official record
Conditions
Pharmacogenetic Testing
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Sep 26, 2026, 1:06 PM EDT
Terminated No phase listed Observational

Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

NCT01232881
View directory record Official record
Conditions
Breast Cancer
Interventions
Tumor Sample, Serum Sample
Procedure
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 27, 2011 · Synced Sep 26, 2026, 1:06 PM EDT
Terminated Phase 1 Interventional

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

NCT01281163
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Positive, Progesterone Receptor Negative, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IV Breast Cancer
Interventions
Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Lapatinib Ditosylate, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
New Haven, Connecticut • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2015 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 2 Interventional Results available

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

NCT02581930
View directory record Official record
Conditions
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Ibrutinib, Laboratory Biomarker Analysis, Pharmacogenomic Study, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 26, 2026, 1:06 PM EDT
Not listed No phase listed Observational

Pharmacogenomic Biomarker Study for Recombinant Human Activated Protein C Treatment in Severe Sepsis

NCT01486524
View directory record Official record
Conditions
Severe Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Sirius Genomics Inc.
Industry
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Not applicable Interventional Results available

A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)

NCT05966142
View directory record Official record
Conditions
Chronic Pain
Interventions
Pharmacogenetic testing, Clinical decisions support
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Gainesville, Florida • Jacksonville, Florida • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 26, 2026, 1:06 PM EDT
Completed No phase listed Observational

Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma

NCT06031194
View directory record Official record
Conditions
Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 26, 2026, 1:06 PM EDT
Recruiting No phase listed Observational

The Texas Interprofessional Pharmacogenomics (IPGx)

NCT06219720
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
50 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 1Phase 2 Interventional

Antenatal Platelet Response on Aspirin: a Pharmacokinetic Study Through Pregnancy

NCT04645004
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 81Mg Non-enteric coated Tab
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
13 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Not applicable Interventional

Implementation Study of Enhanced Medication Therapy Management in Primary Care Practice

NCT02748148
View directory record Official record
Conditions
Medication Therapy Management, Pharmacogenomics
Interventions
Medication therapy management
Other
Lead sponsor
Tabula Rasa HealthCare
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Nicotinic Receptors and Schizophrenia

NCT00952393
View directory record Official record
Conditions
Schizophrenia
Interventions
Pharmacokinetic
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Sep 26, 2026, 1:06 PM EDT
Completed Phase 4 Interventional

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

NCT00140036
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Blood draw
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
29
States / cities
Mobile, Alabama • Tucson, Arizona • Fresno, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2008 · Synced Sep 26, 2026, 1:06 PM EDT
Terminated Not applicable Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

NCT01599832
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Sep 26, 2026, 1:06 PM EDT